Seventh Sense Biosystems has announced that it has obtained CE Mark approval for its Touch Activated Phlebotomy (TAP™) platform for blood collection and testing.
"This first regulatory approval is a significant milestone in our goal of expanding the reach of blood-based point-of-care diagnostics to a majority of patients, regardless of geography or setting," said Howard Weisman, CEO and President of Seventh Sense. "When fully commercialized, the TAP platform will incorporate additional capabilities for sample separation as well as dried blood spot and on-board diagnostic capabilities."
Studies show that a positive patient experience is closely linked to compliance with a prescribed treatment. Seventh Sense will be developing and commercializing novel diagnostic tools that are specially engineered to eliminate the pain and anxiety that can prevent patients from receiving appropriate care.
The company's proprietary innovations in microneedle and microfluidic technology enable the collection of a stable, secure and high quality blood sample without painful lancing or the need for highly skilled medical personnel.
"We've surveyed patients and their physicians around the world and found a significant need for near painless, simple-to-use, and reliable blood collection and diagnostic devices that has so far been unmet," said Weisman.
The company plans to scale-up manufacturing capability in 2014 and continue the development of follow-on products for patients and clinicians in the Americas, Europe and Asia-Pacific regions.